Drug Discovery
As high-throughput screening draws fire, researchers leverage science to put automation into perspective
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
July 26, 2004 Cover
Volume 82, Issue 30
As high-throughput screening draws fire, researchers leverage science to put automation into perspective
Credit:
Pharmaceuticals
Bayer Takes Big Restructure Steps
Firm buys Roche consumer health business, decides to spin off Lanxess
Enzyme Boasts a Radical Makeover
Change may allow pathogen to evade an unwelcoming host's chemical defenses
-
Digital Briefs
New Software and Websites for the Chemical Enterprise
-
From Rags to Riches in China
Petrochemical industry has more cash than it needs to expand and build plants
-
An End to Nuclear Nonproliferation
Terrorism, new weapons, old hostilities threaten to kill off the Nuclear Nonproliferation Treaty
ADVERTISEMENT
Science Concentrates
An Idea Run Amok
Worries about 'gray goo' are misplaced, the originator of the nanotech term now says
